The Latest: Lawyer questions drug company motive with grant

With lawsuits mounting, maker of OxyContin provides grant for nonprofit pharmaceutical company to speed development of lower-cost overdose antidote
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news

Related Links:

Russia has a widespread injection drug use epidemic with high prevalence of HIV and HCV among people who inject drugs (PWID). We conducted a mixed methods study of young (age 18-26) hard drug users in St. Petersburg. Thirty-nine structured and 10 semi-stru...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
The recent rise in opioid overdose deaths in the United States has been attributed to an increase in prescriptions written to patients for chronic pain. Patients with psoriasis have higher rates of comorbidities that may make them more likely to receive a prescription for an opioid, including psoriatic arthritis, obesity, anxiety and depression, but little is known about opioid prescribing practices in adults with psoriasis. We performed a cohort study using OptumInSight's electronic health records database to compare the rate of opioid prescriptions written to patients with psoriasis compared to adults without psoriasis.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Epidemiology Source Type: research
April 19, 2019 -- The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
The money will fund research to test whether hyper-local integrated programs can drastically reduce overdose deaths in those areas within the next 3 yearsMedscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news
US regulators have approved the 1st generic nasal spray version of the overdose reversing drug Narcan
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
FRIDAY, April 19, 2019 -- The first generic naloxone nasal spray to treat opioid overdose has received approval from the U.S. Food and Drug Administration. Teva Pharmaceuticals'lifesaving product is also the first generic naloxone nasal spray...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose. The agency is also planning new steps to prioritize the review of additional generic drug applications for products intended to treat opioid overdose, along with the previously announced action to help facilitate an over-the-counter naloxone product.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Generic drugmaker Teva Pharmaceutical Industries Ltd on Friday received approval from the U.S. Food and Drug Administration (FDA) to market its generic nasal spray for opioid overdose, the health regulator said.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The FDA has granted final approval for the first generic naloxone hydrochloride nasal spray for reversing or stopping the effects from an opioid overdose.FDA Approvals
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Alert Source Type: news
The Food and Drug Administration (FDA) on Friday announced that it granted final approval to the first generic naloxone hydrochloride nasal spray, which can be used to reverse opioid overdoses. The approval is part of the FDA’s wider effort to make tools for stopping or preventing opioid overdoses more accessible and widely used. The agency is also working with drug companies to bring over-the-counter versions of naloxone to market, and is prioritizing the approval of other generic naloxone products. Friday’s announcement, which makes official a tentative approval previously granted to Teva Pharmaceuticals, mea...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Drugs Source Type: news
More News: Grants | Health | Lawsuits | Legislation | Medical Law | Overdose | Oxycodone | OxyContin